← All stories
Markets
What Happened To Cellular Goods (LSE:CBX) And Its Biosynthetic Cannabinoid Ambition?
Highlights The company launched with laboratory-made cannabinoid skincare and ingestible products. Losses well exceeded revenue before the strategy was reconsidered. A rebrand moved the business away from cannabinoids altogether. Cannabinoi…
Covered by 1 outlet
All coverage · 1 article